Valeant completes Salix purchase
This article was originally published in Scrip
The Canadian firm Valeant has completed its acquisition of Salix for $173 per share, giving the deal an enterprise value of $15.8bn. Raleigh, North Carolina-based Salix is now a wholly owned subsidiary of Valeant Pharmaceuticals International. Last month Valeant upped its offer to buy Salix, prompting Endo Pharmaceuticals to withdraw from the battle to acquire the gastro-intestinal focused company. In the next six months Valeant is likely to chop $500m from the combined company's costs through "R&D rationalization" and reductions in corporate overheads. Valeant will also cut Salix's inventory levels, which Salix admitted were unusually high.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.